Demonstrates enantioselective hydride transfer in pyrrolidines, suggesting new routes for medicinal compounds.
We report the oxidative desymmetrization of urea-protected pyrrolidines via site-selective hydride transfer from enantiotopic C–H bonds. The optimal oxoammonium–peptide conjugate catalyst provided over 90% ee across all tested pyrrolidines, providing products that can readily undergo subsequent N-deprotection and other derivatization reactions to form medicinally relevant compounds. We isolated key on-cycle catalytic intermediates, which allowed us to elucidate both the mechanism of catalytic activation and the origin of stereochemical induction in detail. In particular, a stereochemical model for asymmetric induction emerged from analyzing a covalent catalyst–substrate adduct, which served as an isolable analog of the enantiodetermining transition state. In this model, a tight hydrogen bond between the urea protecting group and the peptide directs the asymmetric hydride transfer.
No takes yet. Share an insight, caveat, or question.
Rein et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: